Radius Health (RDUS) Reports Narrower Q4 Loss Than Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Radius Health (RDUS) PT Lifted to $56 at Jefferies; Potentially Early Efficacy Data for RAD1901 at ASCO
March 11, 2015 7:35 AM EDTJefferies analyst Eun K. Yang reiterated a Buy rating and lifted the price target on Radius Health (NASDAQ: RDUS) to $56.00 (from $45.00) following in-line Q4 results but potentially early efficacy data for RAD1901 at ASCO.
Yang commented, "With positive, clean Ph3 data for... More
